Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 662

The DOI matches its Crossref record.

SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy

Maeda, Hiroshi·2001·Advanced Drug Delivery Reviews
DOI 10.1016/s0169-409x(00)00134-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0169-409x(00)00134-4

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 63

  1. Maeda, 1981, Neocarzinostatin in cancer chemotherapy, Anticancer Res., 1, 175
  2. Oda, 1989, Cytotoxicity of SMANCS in comparison with other anticancer agents against various cells in culture, Anticancer Res., 9, 261
  3. Issell, 1979, Zinostatin, Cancer Treat. Rep., 6, 239, 10.1016/S0305-7372(79)80040-7 · doi:10.1016/s0305-7372(79)80040-7
  4. Maeda, 1981, A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid artery, Cancer Chemother. Pharmacol., 5, 243, 10.1007/BF00434392 · DOI
  5. Maeda, 1980, Lymphotropic accumulation of an antitumor antibiotic protein neocarzinostatin, Eur. J. Cancer, 16, 723, 10.1016/0014-2964(80)90215-7 · DOI
  6. Maeda, 1974, Chemical and biological characterization of succinyl neocarzinostatin, J. Antibiot., 27, 303, 10.7164/antibiotics.27.303 · doi:10.7164/antibiotics.27.303
  7. Maeda, 1979, A lipophilic derivative of neocarzinostatin. A polymer conjugation of antitumor protein antibiotic, Int. J. Pept. Protein Res., 14, 81, 10.1111/j.1399-3011.1979.tb01730.x · DOI
  8. Maeda, 1985, Conjugation of poly(styrene-comaleic acid) derivative to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties, J. Med. Chem., 29, 455, 10.1021/jm00382a012 · DOI · Paper page
  9. Maeda, 1988, Improvements of pharmacological properties of protein-drugs by tailoring with synthetic polymers, J. Bioact. Compat. Polym., 3, 27, 10.1177/088391158800300104 · doi:10.1177/088391158800300104
  10. Oda, 1986, Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane, Proc. Soc. Exp. Biol. Med., 181, 9, 10.3181/00379727-181-42218 · DOI
  11. Suzuki, 1988, Interferon induction by SMANCS. A polymer conjugated derivative of neocarzinostatin, Anticancer Res., 8, 97
  12. Suzuki, 1990, Role of natural killer cells and macrophages in the non-specific resistance to tumors in mice stimulated with SMANCS. A polymer-conjugated derivative of neocarzinostatin, Cancer Res., 50, 3897
  13. Takakura, 1987, Disposition and tumor localization of mitomycin C-dextran conjugate in mice, Pharmacol. Res., 4, 293, 10.1023/A:1016489002393 · DOI · Paper page
  14. Sakamoto, 1978, Experimental and clinical studies on the formation of antibody to neocarzinostatin, a new protein antibiotic, Cancer Treat Rep., 62, 2063
  15. Maeda, 1984, Tailor-making of protein drugs by polymer conjugation for tumor targeting, a brief review on SMANCS, J. Protein Chem., 3, 181, 10.1007/BF01040499 · DOI
  16. Maeda, 1975, Degradation of neocarzinostatin by blood sera in vitro and its inhibition by diisopropylfluorophosphate and N-ethylmaleimide, Gann, 66, 523
  17. Hirayama, 1986, Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase: comparative study with neocarzinostatin, Jpn. J. Antibiot., 39, 815
  18. Maeda, 1989, Tumoritropic and lymphotropic principles of macromolecular drugs, Crit. Rev. Ther. Drug Carrier Syst., 6, 193
  19. Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS, Cancer Res., 6, 6387
  20. Suzuki, 1981, A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II, J. Natl. Cancer Inst., 67, 663
  21. Suzuki, 1987, Medial regression and its functional significance in tumor-supplying host arteries, Cancer, 59, 444, 10.1002/1097-0142(19870201)59:3<444::AID-CNCR2820590316>3.0.CO;2-5 · doi:10.1002/1097-0142(19870201)59:3<444::aid-cncr2820590316>3.0.co;2-5
  22. Skinner, 1991, Microvascular architecture of experimental colon tumors in the rat, Cancer Res., 50, 2411
  23. Folkman, 1974, Tumor angiogenesis, Adv. Cancer Res., 19, 331, 10.1016/S0065-230X(08)60058-5 · DOI · Paper page
  24. Folkman, 1987, Angiogenic factors, Science, 235, 442, 10.1126/science.2432664 · DOI · Paper page
  25. Senger, 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid, Science, 219, 983, 10.1126/science.6823562 · DOI · Paper page
  26. Maeda, 1988, Purification and identification of [hydroxypropyl3]bradykinin in ascitic fluid from a patient with gastric cancer, J. Biol. Chem., 263, 16051, 10.1016/S0021-9258(18)37555-0 · DOI
  27. Matsumura, 1988, Involvement of kinin-generating cascade in enhanced vascular permeability in tumor tissue, Jpn. J. Cancer Res., 79, 1327, 10.1111/j.1349-7006.1988.tb01563.x · DOI · Paper page
  28. Iwai, 1984, Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image, Cancer Res., 44, 2114
  29. Kamata, 1985, A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs, Infect. Immunol., 48, 747, 10.1128/IAI.48.3.747-753.1985 · DOI
  30. Maeda, 1989, Pathogenic potentials of bacterial proteases, Clin. Chim. Acta, 185, 357, 10.1016/0009-8981(89)90226-X · doi:10.1016/0009-8981(89)90226-x
  31. Peterson, 1973, Experimental studies on the uptake and retention of labeled proteins in a rat tumor, Eur. J. Cancer, 9, 543, 10.1016/0014-2964(73)90142-4 · DOI
  32. Shibata, 1978, Rat α1-acid glycoprotein: uptake by inflammatory and tumor tissue, Br. J. Exp. Patholol., 59, 601
  33. Kobayashi, 1988, Protein binding of macromolecular anticancer agent SMANCS: characterization of poly(styrene-comaleic acid) derivatives as an albumin binding ligand, J. Bioact. Compat. Polym., 3, 319, 10.1177/088391158800300401 · doi:10.1177/088391158800300401
  34. Konno, 1984, Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium, Cancer, 54, 2367, 10.1002/1097-0142(19841201)54:11<2367::AID-CNCR2820541111>3.0.CO;2-F · DOI · Paper page
  35. Konno, 1983, Effect of arterial administration of high molecular weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report, Eur. J. Cancer Clin. Oncol., 19, 1053, 10.1016/0277-5379(83)90028-7 · DOI · Paper page
  36. Larson, 1978, Mechanism of localization of gallium-67 in tumors, Semin. Nucl. Med., 8, 193, 10.1016/S0001-2998(78)80028-2 · DOI
  37. Matsumura, 1990, Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC, Agents Actions, 29, 172, 10.1007/BF01966443 · doi:10.1007/bf01966443
  38. Maeda, 1990, Kinin-generating cascade in cancer. Clinical and in vitro study and utilization for tumor targeting, J. Cancer Res. Clin. Oncol., 116, 246
  39. Y. Matsumura, K. Maruo, M. Kimura, T. Yamamoto, T. Konno, H. Maeda, Kinin-generating cascade in advanced cancer patients and in vitro study, Jpn. J. Cancer Res., in press.
  40. Armstrong, 1973, Pain in bradykinin: Kalldin and kallikrein, Handb. Exp. Pharmacol., 25, 434
  41. Vergaftig, 1972, Selective inhibition by mepacrine of the release of rabbit aorta contracting substance evoked by the administration of bradykinin, J. Pharm. Pharmacol., 24, 159, 10.1111/j.2042-7158.1972.tb08953.x · doi:10.1111/j.2042-7158.1972.tb08953.x
  42. Lembeck, 1953, 5-Hydroxytryptamine in a carcinoid tumor, Nature, 172, 910, 10.1038/172910a0 · doi:10.1038/172910a0
  43. Greenbaum, 1975, Pepstatin — an inhibitor of leukokinin formation and ascitic fluid accumulation, Cancer Res., 35, 706
  44. Zunino, 1981, Biologic activity of daunorubicin linked to proteins via the methylketone side chain, Tumori, 67, 521, 10.1177/030089168106700602 · doi:10.1177/030089168106700602
  45. Hashida, 1981, Antitumor activity of mitomycin C–dextran conjugate against various murine tumors, Jpn. J. Cancer Res. (Gann), 72, 226
  46. Trouet, 1982, A covalent linkage between daunorubicin and proteins that is stable in serum conjugate: in vitro and in vivo studies, Proc. Natl. Acad. Sci. USA, 79, 626, 10.1073/pnas.79.2.626 · DOI · Paper page
  47. Levi-Schaffer, 1982, Reduced toxicity of daunorubicin by conjugation to dextran, Cancer Treat. Rep., 66, 107
  48. Yamamoto, 1990, Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ether–maleic acid copolymer, Eur. J. Cancer, 26, 253, 10.1016/0277-5379(90)90219-J · doi:10.1016/0277-5379(90)90219-j
  49. Iwai, 1987, Tumor targeting by arterial administration of lipids: rabbit model with VX-2 carcinoma in the liver, Anticancer Res., 7, 321
  50. Oka, 1990, Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation, Pharmacol. Res., 7, 852, 10.1023/A:1015917000556 · DOI
  51. Noda, 1990, Treatment of renal cell carcinoma with intraarterial administration of SMANCS dissolved in Lipiodol, Anticancer Res., 10, 709
  52. Yumoto, 1985, Hepatocellular carcinoma detected by iodized oil, Radiology, 154, 19, 10.1148/radiology.154.1.2981112 · doi:10.1148/radiology.154.1.2981112
  53. Maki, 1985, Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium, Cancer, 56, 751, 10.1002/1097-0142(19850815)56:4<751::AID-CNCR2820560409>3.0.CO;2-Y · DOI
  54. Bartholeyns, 1974, Pancreatic ribonuclease: enzymatic and physiological properties of a cross-linked dimer, Science, 186, 444, 10.1126/science.186.4162.444 · doi:10.1126/science.186.4162.444
  55. Ogino, 1988, Chemical modification of superoxide dismutase. Extension of plasma half-life of the enzyme through its reversible binding to the circulating albumin, Int. J. Pept. Protein Res., 32, 153, 10.1111/j.1399-3011.1988.tb00675.x · doi:10.1111/j.1399-3011.1988.tb00675.x
  56. Takakura, 1989, Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I. Synthesis and characterization, J. Pharm. Sci., 78, 117, 10.1002/jps.2600780209 · doi:10.1002/jps.2600780209
  57. Takakura, 1989, Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II. Biopharmaceutical and pharmacological properties, J. Pharm. Sci., 78, 219, 10.1002/jps.2600780310 · doi:10.1002/jps.2600780310
  58. Kimura, 1988, A new tactic for the treatment of jaundice: an injectable polymer-conjugated bilirubin oxidase, Proc. Soc. Exp. Biol. Med., 188, 364, 10.3181/00379727-188-42747 · DOI
  59. Buys, 1975, Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation, Biochim. Biophys. Acta, 392, 95, 10.1016/0304-4165(75)90169-5 · doi:10.1016/0304-4165(75)90169-5
  60. Kamisaki, 1981, Reduction in immunogenicity and clearance rate of Escherichia coli l-asparaginase by modification with monomethoxypoly(ethylene glycol), J. Pharmacol. Exp. Ther., 216, 410
  61. Ney, 1985, Binding and endocytosis of α2-macroglobulin–plasmin complex, Biochemistry, 24, 4586, 10.1021/bi00338a016 · doi:10.1021/bi00338a016
  62. Comis, 1979, Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans, Cancer Res., 39, 757
  63. Sato, 1991, Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report), Jpn. J. Cancer Chemother., 18, 451

Cited by

See all 662

Metadata

Authors
Maeda, H.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2001-03
Volume
46
Issue
1-3
Pages
169-185
ISSN
0169-409X (ISSN-L)
DOI
10.1016/s0169-409x(00)00134-4
OpenAlex
W1990163407
Cited by
662
References
0
FWCI
1.38
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. https://app.cochat.ai/papers/10.1016/s0169-409x(00)00134-4
The paper
Maeda, H. (2001). SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Advanced Drug Delivery Reviews. https://doi.org/10.1016/s0169-409x(00)00134-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.